Navidea Biopharmaceuticals Announces Positive Results of Second Interim Analysis of Ongoing Phase 2B Study in Rheumatoid Arthritis May 21, 2020
Navidea Biopharmaceuticals Regains Commercialization and Distributions Rights in Europe for LYMPHOSEEK® May 11, 2020
Navidea Biopharmaceuticals to Host First Quarter 2020 Earnings Conference Call and Corporate Update May 7, 2020
Navidea Biopharmaceuticals Signs Letter of Intent with WorldCare Clinical to Partner on Navidea’s Rheumatoid Arthritis Clinical Imaging Workflow and Commercialization; Other Business Updates Mar 31, 2020
Navidea Biopharmaceuticals to Host Fourth Quarter 2019 Earnings Conference Call and Corporate Update Mar 4, 2020
Navidea Biopharmaceuticals Regains Compliance with NYSE American Continued Listing Standards Feb 14, 2020
